MedTrace Logo

Ablative Chemoembolization for Unresectable and Large Hepatocellular Carcinoma

NCT03662841 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 11

Last updated 2023-05-03

No results posted yet for this study

Summary

The objective of this study is to study the safety and tumor response of ACE for large HCC.

Conditions

  • Carcinoma, Hepatocellular

Interventions

PROCEDURE

Ablative chemoembolization (ACE)

Ablative chemoembolization (ACE) using Lipiodol-ethanol and anhydrous cisplatin

Sponsors & Collaborators

  • Chinese University of Hong Kong

    lead OTHER

Principal Investigators

  • Simon Yu · DIIR, CUHK, Hong Kong

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-13
Primary Completion
2023-04-17
Completion
2023-04-28

Countries

  • Hong Kong

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03662841 on ClinicalTrials.gov